Study Group: Angiomax Prescribers for ACS (US)
Council Members in this Study Group: 32
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Charles O'Shaughnessy
Director of Interventional Cardiology
NORTH OHIO HEART CENTER, INC
Charles O'Shaughnessy, MD, is the Director of Interventional Cardiology at North Ohio Heart Center, Ohio. Dr. O'Shaughnessy's clinical interests are in interventional cardiology including balloon angioplasty, laser directional atherectomy, stent placement,...
- Howard Weintraub
Clinical Director
NEW YORK UNIVERSITY (INC)Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub...
- Ramin Ebrahimi
Director of Cardiac Catheterization Lab
Wadsworth VA Medical CenterRamin Ebrahimi, MD, is Associate Clinical Professor at the University of California in Los Angeles. He is also Director of the Cardiac Catheterization Laboratory and Assistant Director of Nuclear Cardiology at the Wadsworth VA Medical Center. Dr. Ebrahimi’s...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 23, 2007
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.
-
Another piece of good news for a very good drug
November 8, 2007
Analysis by: Howard Weintraub, Clinical Director,Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level of BNP. This has not been as successful in patients without myocardial ischemia, but in those with ischemia the shortness of breath and associated chest discomfort has been helped in many. Including the most recent patient with a severe ischemic cardiomyopathy who has responded very very well with a significant increase in his functional capacity. Hopefully this news along with the safety from MERLIN and the A1C data and reduction in arrhythmias in that study will awaken docs to the benefits of Ranexa.
-
November 8, 2007
Analysis by: Howard Weintraub, Clinical Director,Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
-
Good device but not much improvement.
August 31, 2007
St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com
The repositioning of the hole, also present with the VIP version is a mild improvement to decrease sheath manipulation. Otherwise the device has not changed much in the past few years. While a very good device in general, its primary limitaions listed below still remain. 1. not allowing re-access at the previous access site within 90 days of the index procedure 2. inability to promote means for primary healing of the arteriotomy site (primary healing results in much less scar formation and secondary healing that angioseal provides) and 3. relying on an intravascular component for deployment that stays within the vessel for weeks prior to its resolution Newer devices such as the STARCLOSE that also are easy to deploy, rely on no intravascular components and potentially provide much better healing process may be the way of future.
-
June 15, 2007
Analysis by: Howard Weintraub, Clinical Director,FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com
It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in the near and mid-term future. This does not bode well for Sanofi, who will not have to regroup and pray for success with son of Amiodarone.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Other Freestanding Healthcare Facility
- Integrated Healthcare Delivery Network (IDN)
- Contract Research Organization, Independent/Small
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Principal
- Physician - Division Head
- Owner
- Director
- Medical Director